/
Other
Endometriosis
42
Pipeline Programs↗
77
Active Trials↗
44
Companies Involved↗
Endometriosis is a moderately active landscape with 42 programs across 44 companies. The most active players are Kissei Pharmaceutical Co., Ltd., Changchun GeneScience Pharmaceutical Co., Ltd.. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical30
Phase 39
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
38 of 39 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.
Analysis
Trial Status
270
clinical trials
Completed133 · 49%
Recruiting44 · 16%
Unknown status32 · 12%
Not yet recruiting19 · 7%
Terminated18 · 7%
Active, not recruiting11 · 4%
Other13 · 5%
Clinical Trials
Trial Activity
270 trials
Evaluating the Feasibility of elleFA App Implementation
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Preclinical·NCT06452407·20 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)